Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

94 trials

NCT07221838
Recruiting
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
Phase 4 · Germany, Italy, Japan, United States · 11 sites
Registry update: 9 Apr 2026
Conflicting statuses (not updated in the registry for 7 months)
NCT07595653
Recruiting
A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy
Not applicable · Italy · 30 sites
Registry update: 19 May 2026
NCT07250750
Recruiting
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
Phase 1/2 · Bulgaria, Spain, Italy, Poland, Serbia, United States · 26 sites
Registry update: 11 Feb 2026
NCT07215949
Recruiting
Zilucoplan for Severe gMG Exacerbations
Phase 3 · United States · 3 sites
Registry update: 28 Aug 2026
NCT07089121
Recruiting
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Phase 1/2 · United States · 3 sites
Registry update: 27 Jul 2026
NCT07249632
Recruiting
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
Phase 3 · China · 1 site
Registry update: 9 Apr 2026
NCT07217587
Recruiting
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Phase 3 · Austria, Switzerland, Germany, Spain, Israel, Italy, United States · 42 sites
Registry update: 3 Nov 2026
NCT07247279
Recruiting
Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
Not applicable · Russia · 7 sites
Registry update: 14 Oct 2026
NCT07284420
Recruiting
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Phase 2 · Belgium, Germany, Spain, Greece, Italy, Japan, Netherlands, Poland, United States · 39 sites
Registry update: 24 Sept 2026
NCT07294170
Recruiting
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Not applicable · Belgium, Germany, Spain, Greece, Italy, Japan, Poland, United States · 35 sites
Registry update: 26 Oct 2026
NCT07337785
Recruiting
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Early phase 1 · China · 1 site
Registry update: 12 May 2026
NCT07411963
Recruiting
Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG Crisis
Not applicable · France · 8 sites
Registry update: 1 Sept 2026
NCT07403188
Recruiting
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Phase 2/3 · Germany, United States · 5 sites
Registry update: 11 Feb 2026
NCT07072988
Recruiting
Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod
Phase 4 · France · 9 sites
Registry update: 3 Sept 2026
NCT07215650
Recruiting
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
Phase 1 · China · 10 sites
Registry update: 2 Sept 2026
NCT06967480
Recruiting
Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
Not applicable · Italy · 21 sites
Registry update: 5 Feb 2026
NCT07058298
Recruiting
GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
Early phase 1 · China · 1 site
Registry update: 8 Sept 2025
NCT06939166
Recruiting
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
Early phase 1 · China · 1 site
Registry update: 15 Dec 2025
NCT07039916
Recruiting
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Phase 3 · Argentina, Czechia, Germany, Denmark, Spain, United Kingdom, Georgia, Greece, Hungary, Italy, Mexico, Poland, Romania, Serbia, United States · 94 sites
Registry update: 30 Jul 2026
NCT06909253
Recruiting
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
Not applicable · Poland · 10 sites
Registry update: 16 Sept 2026

Ordered by registry start date. Freshness and sponsorship never change the order.